Getein Biotech Inc Market Cap ($631.55 Million)
Market Cap & Net Worth: Getein Biotech Inc (603387)
Getein Biotech Inc market cap. Getein Biotech Inc (SHG:603387) has a market capitalization of $631.55 Million (CN¥4.32 Billion) as of November 9, 2026. Listed on the SHG stock exchange, this China-based company holds position #10741 globally and #2898 in its home market, demonstrating a -0.35% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Getein Biotech Inc's stock price CN¥8.51 by its total outstanding shares 507153517 (507.15 Million). Also see Getein Biotech Inc (603387) cash flow conversion for how efficiently the company converts equity into cash flow.
Getein Biotech Inc Market Cap History (2017–2026)
Getein Biotech Inc market cap history from 2017 to 2026. Data shows growth from $1.05 Billion to $631.55 Million (1.30% CAGR). Check latest Getein Biotech Inc stock price today for real-time trading data and today's change.
Getein Biotech Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Getein Biotech Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset momentum of Getein Biotech Inc to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.59x
Getein Biotech Inc's market cap is 0.59 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2.81x
Getein Biotech Inc's market cap is 2.81 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $1.05 Billion | $488.58 Million | $193.99 Million | 2.15x | 5.41x |
| 2018 | $655.44 Million | $686.24 Million | $249.61 Million | 0.96x | 2.63x |
| 2019 | $808.82 Million | $968.20 Million | $339.67 Million | 0.84x | 2.38x |
| 2020 | $1.22 Billion | $1.12 Billion | $304.73 Million | 1.08x | 3.99x |
| 2021 | $1.01 Billion | $1.40 Billion | $398.99 Million | 0.72x | 2.54x |
| 2022 | $907.15 Million | $1.82 Billion | $498.91 Million | 0.50x | 1.82x |
| 2023 | $816.34 Million | $1.37 Billion | $279.77 Million | 0.60x | 2.92x |
| 2024 | $612.25 Million | $1.16 Billion | $223.64 Million | 0.53x | 2.74x |
| 2025 | $621.16 Million | $1.05 Billion | $220.66 Million | 0.59x | 2.81x |
Competitor Companies of 603387 by Market Capitalization
Companies near Getein Biotech Inc in the global market cap rankings as of November 9, 2026. Also see 603387 total asset value for a full breakdown of the balance sheet.
Key companies related to Getein Biotech Inc by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #109 globally with a market cap of $191.15 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #188 globally with a market cap of $124.99 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #222 globally with a market cap of $109.30 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #233 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #109 | Abbott Laboratories | NYSE:ABT | $191.15 Billion | $109.93 |
| #188 | Stryker Corporation | NYSE:SYK | $124.99 Billion | $325.87 |
| #222 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $101.80 |
| #233 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
Market Capitalization of Getein Biotech Inc (2017–2026)
Market capitalization of Getein Biotech Inc from 2017 to today. Between 2017 and today, Getein Biotech Inc's market cap moved from $1.05 Billion to $ 631.55 Million, with a yearly change of 1.30%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥631.55 Million | +1.67% |
| 2025 | CN¥621.16 Million | +1.45% |
| 2024 | CN¥612.25 Million | -25.00% |
| 2023 | CN¥816.34 Million | -10.01% |
| 2022 | CN¥907.15 Million | -10.59% |
| 2021 | CN¥1.01 Billion | -16.62% |
| 2020 | CN¥1.22 Billion | +50.45% |
| 2019 | CN¥808.82 Million | +23.40% |
| 2018 | CN¥655.44 Million | -37.50% |
| 2017 | CN¥1.05 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 9th, 2026 the market cap of Getein Biotech Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $631.55 Million USD |
| MoneyControl | $631.55 Million USD |
| MarketWatch | $631.55 Million USD |
| marketcap.company | $631.55 Million USD |
| Reuters | $631.55 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Getein Biotech Inc
Getein Biotech, Inc researches, develops, produces, and sells in vitro diagnostic reagents and instruments in China and internationally. The company provides point-of-care detection, chemiluminescence detection, biochemical analysis, molecular testing, thrombus and hemostasis detection, blood cell analysis detection, urine analysis, quality control products, diagnostic raw materials, biochemical … Read more